Reflux inhibitors – new therapy of gastroesophageal reflux disease

Grażyna Jurkowska; Agnieszka Świdnicka-Siergiejko; Andrzej Dąbrowski

doi:10.5114/pg.2012.28645

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2012
vol. 7

Send email

Copy url:

abstract:

Review paper

Reflux inhibitors – new therapy of gastroesophageal reflux disease

Grażyna Jurkowska

,

Agnieszka Świdnicka-Siergiejko

,

Andrzej Dąbrowski

Przegląd Gastroenterologiczny 2012; 7 (2): 57–62

DOI: https://doi.org/10.5114/pg.2012.28645

Online publish date: 2012/05/22

View full text Get citation

PlumX metrics:

The most relevant target for the treatment of refractory gastroesophageal reflux disease (GERD) is controlling the occurrence of transient lower esophageal relaxations (TLESR), which represent the main mechanism of all types of reflux. Drugs in development that have this mechanism of action are now described as reflux inhibitors. The most promising among these appear to be mGluR5 agonists and GABAB receptor agonists, which reduce the number of reflux episodes and improve reflux-related symptoms. Reflux inhibitors appear to have a potential role in the management of refractory GERD as add-on therapy in combination with PPI. Future studies will establish the safety and tolerability of the new anti-reflux therapy.

keywords:

Reflux inhibitors – new therapy of gastroesophageal reflux disease

Grażyna Jurkowska , Agnieszka Świdnicka-Siergiejko , Andrzej Dąbrowski

gastroesophageal reflux, transient lower esophageal sphincter relaxation, GABA receptors, glutamate receptors

Grażyna Jurkowska

,

Agnieszka Świdnicka-Siergiejko

,

Andrzej Dąbrowski